CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
DCV/ASV/BMS-791325 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02175966
NCT02175966Phase 2Completed
CompareCT.gov

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study)

Bristol-Myers Squibb·interventional·Posted Jun 26, 2014·Updated Aug 11, 2020

In Brief

A Phase 2 clinical trial evaluating DCV/ASV/BMS-791325, Ribavirin, and 2 other interventions for Hepatitis C. Completed, enrolled 35 participants across 7 sites.

Detailed Summary

The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 26, 2014
Enrollment StartJul 28, 2014
Primary CompletionJan 28, 2015
Study CompletionDec 17, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.0 years ago

Interventions

DCV/ASV/BMS-791325drug

Ribavirindrug

Sofosbuvirdrug

Peginterferon α-2adrug